TY - JOUR
T1 - The association between GAD65 antibody levels and incident Type 2 Diabetes Mellitus in an adult population: A meta-analysis
AU - Koopman, Anitra D. M.
AU - Beulens, Joline W.
AU - Voerman, Ellis
AU - Rauh, Simone P.
AU - van der Heijden, Amber A.
AU - McDonald, Timothy J.
AU - Langendoen - Gort, Marlous
AU - Rutters, Femke
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Context: Antibodies to the 65 kD isoform of glutamic acid decarboxylase (GAD65) have been associated with incident Type 2 Diabetes Mellitus, however results are inconsistent. Objective: To assess the association between GAD65 antibody positivity and incident Type 2 Diabetes Mellitus in a non-diabetic adult (≥18 years) population, in a systematic review and meta-analysis. Data Sources: A systematic literature search was conducted in Pubmed (MEDLINE) and Embase until January 14th, 2019. Study Selection: Included studies were 1) prospective studies on the association between GAD65 antibodies and incident Type 2 Diabetes Mellitus; 2) in a non-diabetic adult (≥18 years) population. To strengthen the review, unpublished data from 1302 Hoorn Study participants were included. Data Extraction: Data extraction and quality assessment were performed independently by two observers. Ten studies were rated for methodological quality and seven were pooled using a random-effects meta-analysis, of which 2 strong, 2 moderate and 3 of low methodological quality. Data Synthesis: The pooled risk estimate of incident Type 2 Diabetes Mellitus for GAD65 antibody positivity, compared to GAD65 antibody negativity was 3.36 (95% CI: 1.9–5.9). This result was robust to sensitivity analyses. Heterogeneity between studies was significant with I 2 statistic of 79% (p < 0.0001). However, excluding one study showed a decrease of I 2 to 19% (p < 0.0001), explaining a large part of the heterogeneity. Conclusion: GAD65 antibody positivity was associated with an increased risk of future Type 2 Diabetes Mellitus in adults.
AB - Context: Antibodies to the 65 kD isoform of glutamic acid decarboxylase (GAD65) have been associated with incident Type 2 Diabetes Mellitus, however results are inconsistent. Objective: To assess the association between GAD65 antibody positivity and incident Type 2 Diabetes Mellitus in a non-diabetic adult (≥18 years) population, in a systematic review and meta-analysis. Data Sources: A systematic literature search was conducted in Pubmed (MEDLINE) and Embase until January 14th, 2019. Study Selection: Included studies were 1) prospective studies on the association between GAD65 antibodies and incident Type 2 Diabetes Mellitus; 2) in a non-diabetic adult (≥18 years) population. To strengthen the review, unpublished data from 1302 Hoorn Study participants were included. Data Extraction: Data extraction and quality assessment were performed independently by two observers. Ten studies were rated for methodological quality and seven were pooled using a random-effects meta-analysis, of which 2 strong, 2 moderate and 3 of low methodological quality. Data Synthesis: The pooled risk estimate of incident Type 2 Diabetes Mellitus for GAD65 antibody positivity, compared to GAD65 antibody negativity was 3.36 (95% CI: 1.9–5.9). This result was robust to sensitivity analyses. Heterogeneity between studies was significant with I 2 statistic of 79% (p < 0.0001). However, excluding one study showed a decrease of I 2 to 19% (p < 0.0001), explaining a large part of the heterogeneity. Conclusion: GAD65 antibody positivity was associated with an increased risk of future Type 2 Diabetes Mellitus in adults.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85062977321&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30853448
U2 - https://doi.org/10.1016/j.metabol.2019.03.001
DO - https://doi.org/10.1016/j.metabol.2019.03.001
M3 - Review article
C2 - 30853448
SN - 0026-0495
VL - 95
SP - 1
EP - 7
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
ER -